p53 Mutations and Breast Cancer Risk
Author Information
Author(s): Kabat Geoffrey C., Kandel Rita A., Glass Andrew G., Jones Joan G., Olson Neal, Duggan Catherine, Ginsberg Mindy, Negassa Abdissa, Rohan Thomas E.
Primary Institution: Albert Einstein College of Medicine
Hypothesis
Does p53 immunopositivity and genetic alteration in benign breast tissue affect the risk of subsequent breast cancer?
Conclusion
The study found that p53 immunopositivity and genetic alterations were not significantly associated with an increased risk of subsequent breast cancer.
Supporting Evidence
- p53 immunopositivity was not associated with altered risk of subsequent breast cancer.
- Only 4.8% of cases and 5.5% of controls showed any p53 alteration.
- The combination of p53 immunopositivity and nucleotide changes suggested a possible increased risk, but the confidence intervals were very wide.
Takeaway
This study looked at whether changes in a gene called p53 in benign breast tissue could predict breast cancer risk, and it found that they don't really help in telling who might get cancer later.
Methodology
A case-control study nested within a cohort of women biopsied for benign breast disease, analyzing p53 immunopositivity and mutations.
Potential Biases
The study was conducted without knowledge of case-control status, reducing the risk of differential bias.
Limitations
The small number of women with both immunopositivity and genetic alterations limited the ability to draw firm conclusions.
Participant Demographics
Women aged 21 and older with a histopathologic diagnosis of benign breast disease.
Statistical Information
P-Value
4.79
Confidence Interval
0.28–82.31
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website